Issue Date: October 3, 2011
Enzon, NeuroSearch To Slash Jobs
Enzon Pharmaceuticals is slashing its workforce almost in half and cutting its operating costs to better align resources with its R&D activities. By June 2012, after the cuts go into effect, the New Jersey company will have 47 employees. Enzon uses customized PEGylation linker technology and mRNA-targeting agents to develop cancer therapeutics. Separately, Denmark’s NeuroSearch will reduce its workforce from almost 200 currently to about 50 a year from now. The firm is dropping most activities to focus on a Phase III study of its Huntington’s disease drug.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society